D.E. Shaw & Co
EVH icon

D.E. Shaw & Co’s Evolent Health EVH Stock Holding History

D.E. Shaw & Co’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$553K – 5642
2021
Q4 		$553K Hold
20,000
– – ﹤0.01% 4346
2021
Q3 		$620K Buy
+20,000
New +$480K ﹤0.01% 3952

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's EVH Position: Q1 2026 in Review

D.E. Shaw & Co increased its Evolent Health (EVH) stake by 3.1% in Q1 2026, buying an estimated $523K and bringing the position to 5,434,032 shares worth $12.4M. The position accounts for 0.01% of the portfolio, ranked #1464.

D.E. Shaw & Co first reported a position in EVH in Q3 2015 and has held it in 28 quarters since. The position peaked at $23.7M in Q2 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • D.E. Shaw & Co held 5,434,032 shares of Evolent Health worth $12.4M as of Q1 2026.
  • D.E. Shaw & Co bought 164,730 Evolent Health shares in Q1 2026, an estimated $523K.
  • Evolent Health made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1464 holding.
  • D.E. Shaw & Co first reported a position in Evolent Health in Q3 2015 and has held it in 28 quarters since.
  • D.E. Shaw & Co's Evolent Health position peaked at $23.7M in Q2 2025.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.